Objective/Purpose
To evaluate 3 year outcomes of phacoemulsification and endoscopic cyclophotocoagulation (ECP) as a primary surgical treatment for glaucoma and cataract.

Materials/Patients
Patients with coexisting glaucoma and cataract who underwent combined phacoemulsification and endoscopic cyclophotocoagulation were included in this retrospective case note review.

Methods
183 eyes of 176 patients were included in this study. The patients were excluded if presented a previous ocular history of any intraocular surgery or glaucoma laser treatment. Primary outcome measures included IOP, number of antiglaucoma medications, adverse events and the need for glaucoma procedures.

Results and Conclusion
183 eyes of 176 patients were included in this study: 64 eyes (35%) had primary open angle glaucoma, 81 eyes (44.2%) had primary angle closure glaucoma and 38 eyes (20.8%) had pseudoexfoliation glaucoma. The preoperative IOP (17.6 + 6.17 mmHg) was significantly (p<0.01 in all timepoints) greater than in the first postoperative month (14.3 + 5.2 mmHg), and months 3 (14.8 + 5.1 mmHg), 6 (15.3 + 4.6 mmHg), 12 (15.2 + 4.4 mmHg), but was of marginal significance on month 24 (16.1 + 5.1 mmHg), p<0.04), and was not significantly greater in month 36 (16.1 + 4.3 mmHg) (p=0.50). The number of preoperative medications (2.9 + 1.0) decreased significantly (p<0.01) in all timepoints. The most common complications were: fibrinous reaction (7.1%), IOP spike > 30 mmHg (6.6%) and hyphema (1.1%). 6 eyes needed further surgery to control the IOP. In conclusion, Phacoemulsification associated with endoscopic cyclophotocoagulation is safe and effective as a primary procedure for combined glaucoma and cataract that can significantly decrease the need of antiglaucoma medications.

[ Keyword ]
Glaucoma / Endoscopic cyclophotocoagulation

[ Conflict of Interest ]
No